Revolo Biotherapeutics
Developing revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
£40.6m | Series B | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Revolo Biotherapeutics is a pioneering biotherapeutics company focused on transforming the treatment landscape for autoimmune and allergic diseases. The company develops innovative therapies designed to reset the immune system, aiming for long-term disease remission after just a single administration. Revolo Biotherapeutics serves patients suffering from various autoimmune and allergic conditions, operating within the biopharmaceutical market. The company's business model revolves around drug discovery and development, leveraging its unique disease-agnostic approach to create groundbreaking treatments. Revenue is generated through the development and commercialization of these therapies, as well as potential partnerships and licensing agreements. With headquarters in Gaithersburg, MD, USA, and London, UK, Revolo Biotherapeutics has a global footprint and is led by a team of seasoned experts in immunology and biopharmaceuticals.
Keywords: autoimmune diseases, allergic diseases, immune system reset, biotherapeutics, drug discovery, long-term remission, innovative therapies, global footprint, immunology, biopharmaceuticals.